Craig Bijou
Stock Analyst at B of A Securities
(3.82)
# 540
Out of 4,818 analysts
61
Total ratings
61.76%
Success rate
59.85%
Average return
Main Sectors:
Stocks Rated by Craig Bijou
Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
RXST RxSight | Maintains: Buy | $60 → $36 | $14.48 | +148.62% | 1 | Mar 21, 2025 | |
TFX Teleflex | Downgrades: Underperform | $235 → $140 | $133.00 | +5.26% | 5 | Mar 4, 2025 | |
BLCO Bausch + Lomb | Maintains: Underperform | $18 → $17 | $12.78 | +33.07% | 3 | Feb 20, 2025 | |
GMED Globus Medical | Upgrades: Neutral | $80 → $97 | $71.90 | +34.91% | 4 | Jan 9, 2025 | |
IART Integra LifeSciences Holdings | Maintains: Underperform | $26 → $18 | $16.32 | +10.33% | 13 | Oct 7, 2024 | |
ITGR Integer Holdings | Maintains: Buy | $135 → $145 | $120.49 | +20.34% | 3 | Oct 1, 2024 | |
MMSI Merit Medical Systems | Maintains: Neutral | $92 → $103 | $93.79 | +9.82% | 3 | Sep 16, 2024 | |
HAE Haemonetics | Initiates: Neutral | $85 | $60.34 | +40.87% | 1 | Sep 11, 2024 | |
PRCT PROCEPT BioRobotics | Maintains: Buy | $80 → $94 | $55.70 | +68.76% | 3 | Aug 22, 2024 | |
GEHC GE HealthCare Technologies | Maintains: Neutral | $94 → $86 | $64.89 | +32.53% | 2 | May 1, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $80.94 | +17.37% | 1 | Oct 30, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $36 | $13.89 | +159.18% | 2 | Jan 18, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 → $45 | $7.47 | +502.41% | 3 | May 13, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1 → $8 | $0.40 | +1,886.59% | 2 | Mar 25, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $30 | $6.58 | +355.93% | 5 | Mar 24, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $17 → $13 | $8.82 | +47.39% | 2 | Mar 24, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $48 → $42 | $13.48 | +211.57% | 3 | Feb 25, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $207 → $230 | $487.93 | -52.86% | 1 | Jan 10, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $230 | $357.11 | -35.59% | 4 | Jul 26, 2019 |
RxSight
Mar 21, 2025
Maintains: Buy
Price Target: $60 → $36
Current: $14.48
Upside: +148.62%
Teleflex
Mar 4, 2025
Downgrades: Underperform
Price Target: $235 → $140
Current: $133.00
Upside: +5.26%
Bausch + Lomb
Feb 20, 2025
Maintains: Underperform
Price Target: $18 → $17
Current: $12.78
Upside: +33.07%
Globus Medical
Jan 9, 2025
Upgrades: Neutral
Price Target: $80 → $97
Current: $71.90
Upside: +34.91%
Integra LifeSciences Holdings
Oct 7, 2024
Maintains: Underperform
Price Target: $26 → $18
Current: $16.32
Upside: +10.33%
Integer Holdings
Oct 1, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $120.49
Upside: +20.34%
Merit Medical Systems
Sep 16, 2024
Maintains: Neutral
Price Target: $92 → $103
Current: $93.79
Upside: +9.82%
Haemonetics
Sep 11, 2024
Initiates: Neutral
Price Target: $85
Current: $60.34
Upside: +40.87%
PROCEPT BioRobotics
Aug 22, 2024
Maintains: Buy
Price Target: $80 → $94
Current: $55.70
Upside: +68.76%
GE HealthCare Technologies
May 1, 2024
Maintains: Neutral
Price Target: $94 → $86
Current: $64.89
Upside: +32.53%
Oct 30, 2023
Initiates: Buy
Price Target: $95
Current: $80.94
Upside: +17.37%
Jan 18, 2022
Maintains: Buy
Price Target: $43 → $36
Current: $13.89
Upside: +159.18%
May 13, 2020
Reiterates: Overweight
Price Target: $23 → $45
Current: $7.47
Upside: +502.41%
Mar 25, 2020
Maintains: Overweight
Price Target: $1 → $8
Current: $0.40
Upside: +1,886.59%
Mar 24, 2020
Maintains: Neutral
Price Target: $60 → $30
Current: $6.58
Upside: +355.93%
Mar 24, 2020
Reiterates: Overweight
Price Target: $17 → $13
Current: $8.82
Upside: +47.39%
Feb 25, 2020
Maintains: Neutral
Price Target: $48 → $42
Current: $13.48
Upside: +211.57%
Jan 10, 2020
Reiterates: Overweight
Price Target: $207 → $230
Current: $487.93
Upside: -52.86%
Jul 26, 2019
Maintains: Neutral
Price Target: $190 → $230
Current: $357.11
Upside: -35.59%